13F Pro13F Pro

SEC Form 4 reporting owner

EcoR1 Capital, LLC

EcoR1 Capital, LLC has filed 17 Form 4 transactions reported between January 12, 2026 and November 18, 2026, as a reporting owner of ANAPTYSBIO, INC, 10% owner of Atara Biotherapeutics, Inc., 10% owner of First Tracks Biotherapeutics, Inc. and Director of Aktis Oncology, Inc..

Name as filed: EcoR1 Capital, LLC

Follow EcoR1 Capital, LLC and get an alert on every new Form 4

EcoR1 Capital, LLC holds 8.3M shares of ANAB, worth $391.3M, 27.77% of the company.

As of their Nov 16, 2026 Form 4 (filed Nov 18, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $47.40 · 29.7M shares outstanding on Nov 9, 2026

EcoR1 Capital, LLC holds at least 3.2M shares of TRAX, worth $141.1M, 7.56% of the company.

As of their Apr 20, 2026 Form 4 · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $44.46 · 42.0M shares outstanding on Oct 29, 2026

Counted from the latest direct line and the latest indirect line that traded. Shares held through other trusts or entities that did not trade are not included yet, so the true holding can be larger.

EcoR1 Capital, LLC holds at least 1.6M shares of ATRA, worth $9.8M, 15.23% of the company.

As of their May 7, 2026 Form 4 · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $6.34 · 10.2M shares outstanding on Nov 6, 2026

Counted from the latest direct line and the latest indirect line that traded. Shares held through other trusts or entities that did not trade are not included yet, so the true holding can be larger.

Holdings in 1 more company are listed under Roles and reported holdings below.

Open-market buys, 24 mo
$62.0M
6 lines
Open-market sales, 24 mo
$65.0M
1 lines
Companies
4
with Form 4 filings
Latest transaction
Nov 18, 2026
transaction date

Roles and reported holdings

  • ANABANAPTYSBIO, INC
    Nov 16, 2026 – Nov 18, 2026

    Reporting owner

    See Note8,254,674 sh

    As of Nov 16, 2026 · Form 4

    24 months: $17.2M bought

  • ATRAAtara Biotherapeutics, Inc.
    May 7, 2026

    10% owner

    Indirect (latest line that moved)1,552,000 sh

    As of May 7, 2026 · Form 4

    24 months: $4.7M bought

  • TRAXFirst Tracks Biotherapeutics, Inc.
    Apr 20, 2026

    10% owner

    Indirect (latest line that moved)3,174,519 sh

    As of Apr 20, 2026 · Form 4

    24 months: $65.0M sold

  • AKTSAktis Oncology, Inc.
    Jan 12, 2026

    Director

    Indirect (latest line that moved)347,305 sh

    As of Jan 12, 2026 · Form 4

    24 months: $40.0M bought

How their buys did since

6 open-market purchases against today’s price: -6.8% on average, -7.3% weighted by dollars spent.

DatePaidReturn
Nov 18, 2026ANAB$46.54+1.8%now $47.40
Nov 17, 2026ANAB$45.66+3.8%now $47.40
Nov 16, 2026ANAB$45.66+3.8%now $47.40
May 7, 2026ATRA$9.35-32.2%now $6.34
Jan 12, 2026AKTS$18.00-8.9%now $16.40
Jan 12, 2026AKTS$18.00-8.9%now $16.40

Each purchase at the price on its Form 4, against the latest trade or close, adjusted for stock splits. Past returns say nothing about future ones.

Transaction history

All 17 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Nov 18, 2026ANABOpen-market purchaseCode P · indirect138,093$6.4M@ $46.54Form 4
Nov 17, 2026ANABOpen-market purchaseCode P · indirect152,367$7.0M@ $45.66Form 4
Nov 16, 2026ANABOpen-market purchaseCode P · indirect84,120$3.8M@ $45.66Form 4
May 7, 2026ATRA10% ownerOpen-market purchaseCode P · indirect507,407$4.7M@ $9.35Form 4
Apr 20, 2026TRAX10% ownerOpen-market saleCode S · indirect4,705,575$65.0M@ $13.81Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect86,222—Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect965,190—Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect102,500—Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect2,397,500—Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect488,891—Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect997,299—Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect9,913,810—Form 4
Jan 12, 2026AKTSDirectorOpen-market purchaseCode P · indirect144,443$2.6M@ $18.00Form 4
Jan 12, 2026AKTSDirectorOpen-market purchaseCode P · indirect2,077,779$37.4M@ $18.00Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect128,506—Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect202,862—Form 4
Jan 12, 2026AKTSDirectorConversion of derivativeCode C · indirect2,270,879—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares each ownership line is left at by the person’s latest Form 4, 4/A or 5: held directly, and through each trust or entity named on the filing. A second class of common stock that converts into the listed one counts as shares; options and restricted stock units are listed but not counted. Value uses the latest trade or close, and the share of the company uses the latest shares-outstanding count the company reported. Where a filing has not yet been read line by line, the figure comes from the latest direct and indirect lines that traded and is shown as “at least”.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.